Search - tctmd.com

Displaying 61 - 80 of 273

Sort: Relevancy | Date

Presentation TCT 2016

Evolut R and 2.0: Design Features, Special Attributes, and Clinical Trial Program

Presenter: Eberhard Grube, James B. Hermiller Jr., Jeffrey J. Popma

November 01, 2016

Presentation TCT 2016

FDA Perspectives on Short DAPT IDE Trials

Presenter: Michael C. John, Gregg W. Stone, Andrew Farb

November 01, 2016

Presentation TCT 2016

Highlights (And my Interpretations) From: DES Comparisons BIO-RESORT (TWENTE III) and BIONICS

Presenter: Philip M. Urban, Stephen G. Worthley, Sigmund Silber

November 01, 2016

Presentation TCT 2016

FDA Regulatory Considerations for Novel and Not-So-Novel New Metallic DES and Bioresorbable Scaffolds

Presenter: Michael C. John, Gregg W. Stone, P.F. Adrian Magee

November 01, 2016

Presentation TCT 2016

Sapien 3 and ULTRA: Design Features, Special Attributes, and Clinical Trial Program

Presenter: Eberhard Grube, James B. Hermiller Jr., John G. Webb

November 01, 2016

Presentation TCT 2016

Complications Related to Contrast and Commonly Used Medications

Presenter: Giora Weisz, Payam Dehghani

November 01, 2016

Presentation TCT 2016

Statistics and Clinical Study Design: Teaching Through Experience

Presenter: Stuart J. Pocock, Binita Shah

November 01, 2016

Presentation TCT 2016

2016 CTO Revascularization Update

Presenter: Sripal Bangalore, George D. Dangas, Khaldoon Alaswad

November 01, 2016

Presentation TCT 2016

Opening Salvo: I Don't Believe That Door-to-Balloon Time Is a Critical Metric for Primary PCI In 2016!

Presenter: David J. Cohen, Ajay J. Kirtane, Alan C. Yeung, Hitinder S. Gurm

November 01, 2016

Presentation TCT 2016

2016 STEMI PCI Update: Evidence and Guidelines

Presenter: Sripal Bangalore, George D. Dangas, Sanjit S. Jolly

November 01, 2016

Presentation TCT 2016

2016 DAPT Update: Evidence and Guidelines

Presenter: Sripal Bangalore, George D. Dangas, Adnan K. Chhatriwalla

November 01, 2016

Presentation TCT 2016

Bioabsorbable Vascular Scaffolds: Landscape in 2016

Presenter: Sripal Bangalore, George D. Dangas, Alexandre Abizaid

November 01, 2016

Presentation TCT 2016

My Most Challenging Case 2016: STEMI with Multivessel Disease

Presenter: Shao-Liang Chen, Ajay J. Kirtane, Manish A. Parikh, Bo Xu, Ning Guo

October 31, 2016

Presentation TCT 2016

Complications 5. Bleeding after TAVR: Incidence, Prognostic Importance, Predictors, and Associations

Presenter: Neil E. Moat, John G. Webb, Philippe Généreux

October 31, 2016

Presentation TCT 2016

Strategies to Reduce the Frequency of New Pacemakers After TAVR: Imaging, Procedural, and Device-Related Factors

Presenter: Neil E. Moat, John G. Webb, Ian T. Meredith

October 31, 2016

Presentation TCT 2016

My Most Challenging Case 2016: Severe LV Dysfunction

Presenter: Shao-Liang Chen, Ajay J. Kirtane, Manish A. Parikh, Bo Xu, Qi Zhang

October 31, 2016

Presentation TCT 2016

Complications 4. Conduction Disturbances: Clinical Implications of New LBBB and New Pacemakers After TAVR

Presenter: Neil E. Moat, John G. Webb, Marina Urena

October 31, 2016

Presentation TCT 2016

Trial #9 - The Essentials ofIN.PACT SFA: 3-year Outcomes of a Paclitaxel-Coated Balloon for Femoropopliteal Lesions

Presenter: William A. Gray, Stephan Windecker, John R. Laird Jr.

October 31, 2016

Presentation TCT 2016

Strokes and TAVR: Is Stroke Frequency Declining? Etiologic Factors Clinical, Anatomic, Technique-related, and Device-specific

Presenter: Neil E. Moat, John G. Webb, Samir R. Kapadia

October 31, 2016

Presentation TCT 2016

My Most Challenging Case 2016: Chronic Total Occlusion

Presenter: Shao-Liang Chen, Ajay J. Kirtane, Manish A. Parikh, Bo Xu, Bin Zhang

October 31, 2016

Advertisement

Evolut R and 2.0: Design Features, Special Attributes, and Clinical Trial Program

FDA Perspectives on Short DAPT IDE Trials

Highlights (And my Interpretations) From: DES Comparisons BIO-RESORT (TWENTE III) and BIONICS

FDA Regulatory Considerations for Novel and Not-So-Novel New Metallic DES and Bioresorbable Scaffolds

Sapien 3 and ULTRA: Design Features, Special Attributes, and Clinical Trial Program

Complications Related to Contrast and Commonly Used Medications

Statistics and Clinical Study Design: Teaching Through Experience

2016 CTO Revascularization Update

Opening Salvo: I Don't Believe That Door-to-Balloon Time Is a Critical Metric for Primary PCI In 2016!

2016 STEMI PCI Update: Evidence and Guidelines

2016 DAPT Update: Evidence and Guidelines

Bioabsorbable Vascular Scaffolds: Landscape in 2016

My Most Challenging Case 2016: STEMI with Multivessel Disease

Complications 5. Bleeding after TAVR: Incidence, Prognostic Importance, Predictors, and Associations

Strategies to Reduce the Frequency of New Pacemakers After TAVR: Imaging, Procedural, and Device-Related Factors

My Most Challenging Case 2016: Severe LV Dysfunction

Complications 4. Conduction Disturbances: Clinical Implications of New LBBB and New Pacemakers After TAVR

Trial #9 - The Essentials ofIN.PACT SFA: 3-year Outcomes of a Paclitaxel-Coated Balloon for Femoropopliteal Lesions

Strokes and TAVR: Is Stroke Frequency Declining? Etiologic Factors Clinical, Anatomic, Technique-related, and Device-specific

My Most Challenging Case 2016: Chronic Total Occlusion

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content